Levicept's LEVI-04 Shows Dual Benefit in Osteoarthritis: Reduces Bone Marrow Lesions While Alleviating Pain
Key Insights
Levicept's Phase II trial of LEVI-04 demonstrated significant, dose-dependent reduction in bone marrow lesion presence and area compared to placebo in 518 osteoarthritis patients.
Changes in bone marrow lesion area were significantly correlated with improvements in patient-reported symptoms including pain relief.
The novel neurotrophin-3 inhibitor represents a first-in-class biologic treatment that simultaneously modifies joint structure and alleviates osteoarthritis symptoms.
Levicept Ltd (search) announced that its novel neurotrophin-3 inhibitor LEVI-04 demonstrated significant structural and symptomatic benefits in a large Phase II osteoarthritis trial, with new data showing dose-dependent reductions in bone marrow lesions alongside pain relief. The findings will be presented at the American College of Rheumatology's ACR Convergence 2025 meeting in Chicago from October 24-29.
Phase II Trial Results Show Dual Mechanism Benefits
The multiarm, multicentre, randomized, double-blind, placebo-controlled Phase II study enrolled 518 participants with pain and disability due to knee osteoarthritis (ClinicalTrials.gov ID: NCT05618782). The trial revealed a significant, dose-dependent reduction in bone marrow lesion presence and area for LEVI-04 compared with placebo in patients with osteoarthritis.
Importantly, changes in bone marrow lesion area were significantly correlated with changes in patient-reported symptoms including pain, suggesting a direct relationship between structural joint improvements and clinical benefits.
Professor Philip Conaghan, MBBS, PhD, Director NIHR Leeds Biomedical Research Centre and Principal Investigator, emphasized the significance of these findings: "For the first time, we will show findings which suggest that LEVI-04 holds promise as a therapy to provide contemporaneous modification of joint structure - bone marrow lesions - and symptoms of OA including pain."
First-in-Class Neurotrophin-3 Inhibitor
LEVI-04 represents a first-in-class novel biologic under development as a non-addictive pain treatment. The drug works by inhibiting NT-3, one of the neurotrophin family of proteins. Previously presented data from the same trial showed that the primary efficacy endpoint was met with significant analgesia across all doses, accompanied by a favorable safety and tolerability profile.
Comprehensive Data Presentation at ACR Convergence 2025
Levicept will present multiple aspects of LEVI-04's clinical profile across four presentations:
The primary presentation, "LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT," will be delivered as an oral plenary presentation on Monday, October 27, from 08:45-09:00 CST.
Additional poster presentations will cover the drug's pharmacology, radiologic surveillance methodology, and functional outcomes including results from the Staircase-Evoked Pain Procedure (StEPP), demonstrating clinically meaningful improvements in pain and physical function across a range of osteoarthritis outcomes.
Market Potential and Development Status
Conaghan noted that these studies "add to the evidence of LEVI-04's potential to offer a vital new treatment option for millions of patients worldwide in need." The company estimates that the market opportunity for drugs treating osteoarthritis exceeds $10 billion.
LEVI-04 was discovered by Levicept's founder Simon Westbrook, and the company's investors include Medicxi (search), Advent Life Sciences (search), Gilde Healthcare (search), and Pfizer Ventures (search). The biotechnology company is based in the UK and focuses specifically on developing LEVI-04 as a treatment for osteoarthritis and chronic pain.